paroxetine has been researched along with Recrudescence in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 26 (46.43) | 18.2507 |
| 2000's | 21 (37.50) | 29.6817 |
| 2010's | 9 (16.07) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amrein, R; Arias-Carrión, O; Carta, MG; Dias, GP; Freire, RC; Machado, S; Mochcovitch, MD; Nardi, AE; Versiani, M | 1 |
| Berk, M; Dodd, S; Kelin, K; Mancini, M; Schacht, A | 1 |
| IsHak, WW; Karamians, R; Peselow, ED; Pizano, D; Tobia, G | 1 |
| Patterson, B; Van Ameringen, M | 1 |
| Ba-M'hamed, S; Bennis, M; Bentefour, Y; Garcia, R; Rakibi, Y | 1 |
| Abi-Jaoude, E; Healy, D; Jureidini, J; Le Noury, J; Nardo, JM; Raven, M; Tufanaru, C | 1 |
| Kim, SH; Lee, HY; Lee, MS | 1 |
| Bienfait, K; Buyske, S; Dicke, A; Dobkin, RD; Gara, M; Marin, H; Mark, MH; Menza, M | 1 |
| Parish, SJ | 1 |
| LeBlanc, SR; Ovanessian, MM; Parikh, SV | 1 |
| Nibuya, M; Nomura, S; Takahashi, T | 1 |
| Beeské, S; Griebel, G; Stahl, SM | 1 |
| Hair, T; Kumar, R; Stein, DJ; Versiani, M | 1 |
| Biederman, J; Carpenter, D; Emslie, G; Farrell, C; Geller, DA; Mullin, B; Stewart, SE; Wagner, KD | 1 |
| Malik, AR; Ravasia, S; Wolf, PK | 1 |
| Albert, A; De Bruyckere, K; Demyttenaere, K; Dewé, W; Mesters, P; Sangeleer, M | 1 |
| Basinski, J; Butters, MA; Dew, MA; Driscoll, HC; Houck, PR; Mazumdar, S; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Schlernitzauer, MA; Stack, JA | 1 |
| Kozian, R | 1 |
| Gorodnichev, AV; Kostiukova, EG; Mosolov, SN; Timofeev, IV | 1 |
| Appelhof, BC; Brouwer, JP; Fliers, E; Hoogendijk, WJ; Huyser, J; Schene, AH; Tijssen, JG; van Dyck, R; Verweij, M; Wiersinga, WM | 1 |
| Dew, MA; Dombrovski, AY; Houck, PR; Lenze, EJ; Mulsant, BH; Pollock, BG; Reynolds, CF | 1 |
| Hirschfeld, RM | 1 |
| O'Brien, JT | 1 |
| Alpert, JE; Fava, M; Maddocks, A; Rosenbaum, JF | 1 |
| Domino, EF; Holmes, RD; Lee, A; Markel, H | 1 |
| Nemeroff, CB | 1 |
| Duboff, EA | 1 |
| Dunbar, G; Montgomery, SA | 1 |
| Kupfer, DJ | 1 |
| Crosby, J; Flint, AJ; Genik, JL | 1 |
| Abed, RT; Ascher, A; Baldwin, DS; Buckingham, SA; Cox, J; Hawley, CJ; Maragakis, BP; Pover, GH | 1 |
| Cirillo-Marucco, E; Corvasce, A; Ludovico, GM; Marano, A; Pagliarulo, A; Pagliarulo, G | 1 |
| Begley, A; Cornes, C; Dew, MA; Frank, E; Hall, M; Houck, PR; Kupfer, DJ; Mazumdar, S; Miller, MD; Mulsant, B; Perel, JM; Reynolds, CF; Shear, MK | 1 |
| Castañeda, R; Levy, R; Sussman, N; Westreich, LM | 1 |
| Bech, P; Black, C; Clemmesen, L; Lauritzen, L; Lunde, M; Odgaard, K; Ohrström, J | 1 |
| Huidobro, A; Sanz-Fuentenebro, FJ; Tejadas-Rivas, A | 1 |
| Kraus, RP | 1 |
| Adès, J; Lejoyeux, M | 1 |
| Fekkes, D; Hengeveld, MW; Kerkhof, AJ; Tuyl, JP; Van der Mast, RC; Van Kempen, GM; Verkes, RJ; Zwinderman, AH | 1 |
| Flint, A | 1 |
| Hengeveld, MW; Tuyl, JP; Van der Mast, RC; Van Kempen, GM; Verkes, RJ; Zwinderman, AH | 1 |
| Franchini, L; Gasperini, M; Perez, J; Smeraldi, E; Zanardi, R | 1 |
| Stein, MB | 1 |
| Davidson, JR | 1 |
| Bentkover, JD; Feighner, JP | 1 |
| Bartel, RL; Goodhue, A; Smith, NB | 1 |
| Begley, AE; Bump, GM; Dew, MA; Mazumdar, S; Mulsant, BH; Pollock, BG; Reynolds, CF | 1 |
| Aberg-Wistedt, A; Khoury, AE; Stain-Malmgren, R; Tham, A | 1 |
| Klein, RM; Walker, JB; Yee, SL | 1 |
| Baldwin, DS; Hawley, CJ; Mellors, K | 1 |
| Hubrich-Ungureanu, P; Knopf, U; Thome, J | 1 |
| Fonseca, R; Tefferi, A | 1 |
| Culpepper, L | 1 |
8 review(s) available for paroxetine and Recrudescence
| Article | Year |
|---|---|
Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder.
Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Paroxetine; Recurrence; Thiophenes; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Guidelines for the long-term treatment of depression.
Topics: Adult; Amitriptyline; Antidepressive Agents; Clinical Trials as Topic; Combined Modality Therapy; Depressive Disorder; Drug Administration Schedule; Female; Fluoxetine; Follow-Up Studies; Humans; Imipramine; Middle Aged; Paroxetine; Placebos; Psychotherapy; Recurrence; Time Factors; Treatment Outcome | 1994 |
Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression.
Topics: Adolescent; Adult; Aged; Animals; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Paroxetine; Recurrence | 1993 |
Management of recurrent depression.
Topics: 1-Naphthylamine; Antidepressive Agents; Chronic Disease; Combined Modality Therapy; Depressive Disorder; Drug Administration Schedule; Fluoxetine; Humans; Imipramine; Paroxetine; Psychotherapy; Recurrence; Sertraline | 1993 |
Antidepressant discontinuation: a review of the literature.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder; Fluoxetine; Humans; Incidence; Monoamine Oxidase Inhibitors; Paroxetine; Recurrence; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Syndrome; Venlafaxine Hydrochloride | 1997 |
Medication treatments for panic disorder and social phobia.
Topics: Antidepressive Agents, Tricyclic; Benzamides; Benzodiazepines; Citalopram; Clinical Trials as Topic; Clomipramine; Clonazepam; Dose-Response Relationship, Drug; Female; Humans; Male; Moclobemide; Monoamine Oxidase Inhibitors; Panic Disorder; Paroxetine; Piperidines; Recurrence; Selective Serotonin Reuptake Inhibitors; Social Behavior Disorders | 1998 |
The long-term treatment of panic disorder.
Topics: Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Clomipramine; Cognitive Behavioral Therapy; Drug Administration Schedule; Follow-Up Studies; Humans; Long-Term Care; Panic Disorder; Paroxetine; Recurrence; Relaxation Therapy; Treatment Outcome | 1998 |
Generalized anxiety disorder in primary care: emerging issues in management and treatment.
Topics: Adaptation, Psychological; Adolescent; Adult; Anxiety Disorders; Cognitive Behavioral Therapy; Comorbidity; Cyclohexanols; Depressive Disorder; Female; Humans; Male; Middle Aged; Paroxetine; Physicians, Family; Prevalence; Primary Health Care; Recurrence; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; United States; Venlafaxine Hydrochloride | 2002 |
22 trial(s) available for paroxetine and Recrudescence
| Article | Year |
|---|---|
A 6-Year Posttreatment Follow-up of Panic Disorder Patients: Treatment With Clonazepam Predicts Lower Recurrence Than Treatment With Paroxetine.
Topics: Adult; Clonazepam; Female; Follow-Up Studies; GABA Modulators; Humans; Male; Middle Aged; Panic Disorder; Paroxetine; Predictive Value of Tests; Prospective Studies; Recurrence; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2017 |
Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Imipramine; Male; Paroxetine; Psychiatric Status Rating Scales; Recurrence | 2016 |
The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depression; Disability Evaluation; Double-Blind Method; Female; Humans; Male; Middle Aged; Nortriptyline; Parkinson Disease; Paroxetine; Psychiatric Status Rating Scales; Quality of Life; Recurrence; Treatment Outcome | 2009 |
Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Personality Assessment; Phobic Disorders; Recurrence; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2002 |
Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?
Topics: Adolescent; Child; Comorbidity; Double-Blind Method; Female; Humans; Male; Mental Disorders; Obsessive-Compulsive Disorder; Paroxetine; Psychiatric Status Rating Scales; Recurrence; Selective Serotonin Reuptake Inhibitors | 2003 |
[Comparative efficacy and tolerability of paroxetine and amitriptiline in long-term therapy preventing depressive recurrences].
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Data Interpretation, Statistical; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Quality of Life; Recurrence; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome | 2005 |
Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression).
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Corticotropin-Releasing Hormone; Depressive Disorder, Major; Dexamethasone; Double-Blind Method; Female; Follow-Up Studies; Glucocorticoids; Humans; Hydrocortisone; Male; Middle Aged; Paroxetine; Pituitary-Adrenal Function Tests; Predictive Value of Tests; Psychiatric Status Rating Scales; Recurrence; Regression Analysis; Time Factors | 2006 |
Maintenance treatment for old-age depression preserves health-related quality of life: a randomized, controlled trial of paroxetine and interpersonal psychotherapy.
Topics: Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Follow-Up Studies; Humans; Interpersonal Relations; Male; Paroxetine; Psychotherapy, Brief; Quality of Life; Recurrence; Retrospective Studies; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2007 |
Childhood psychopathology retrospectively assessed among adults with early onset major depression.
Topics: 1-Naphthylamine; Adolescent; Adult; Anxiety Disorders; Child; Child Behavior Disorders; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Imipramine; Male; Mental Disorders; Middle Aged; Paroxetine; Personality Development; Phobic Disorders; Recurrence; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 1994 |
Long-term treatment of major depressive disorder with paroxetine.
Topics: Adolescent; Adult; Aged; Depressive Disorder; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Paroxetine; Personality Inventory; Recurrence | 1993 |
Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression.
Topics: Adult; Aged; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Recurrence; Time Factors; Treatment Outcome | 1993 |
A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Recurrence; Severity of Illness Index; Treatment Outcome; Triazoles | 1996 |
High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression.
Topics: Age Factors; Age of Onset; Aged; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Hospitalization; Humans; Lithium; Male; Nortriptyline; Paroxetine; Perphenazine; Placebos; Psychotherapy; Recurrence; Risk Factors; Treatment Outcome | 1996 |
Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Denmark; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electroconvulsive Therapy; Female; Follow-Up Studies; Humans; Imipramine; Male; Middle Aged; Paroxetine; Personality Inventory; Recurrence; Treatment Outcome | 1996 |
The impact of treatment resistance on depressive relapse following electroconvulsive therapy.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Combined Modality Therapy; Depressive Disorder; Electroconvulsive Therapy; Humans; Imipramine; Paroxetine; Recurrence; Treatment Outcome | 1997 |
Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression.
Topics: Adult; Anger; Depression; Double-Blind Method; Female; Humans; Male; Mental Disorders; Paroxetine; Patient Dropouts; Personality Disorders; Placebos; Recurrence; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide Prevention; Suicide, Attempted; Treatment Outcome | 1998 |
Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study.
Topics: Adult; Age of Onset; Ambulatory Care; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Proportional Hazards Models; Psychiatric Status Rating Scales; Recurrence; Selective Serotonin Reuptake Inhibitors; Survival Analysis; Treatment Outcome | 1998 |
Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly.
Topics: Adrenergic Uptake Inhibitors; Aged; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Nortriptyline; Paroxetine; Psychiatric Status Rating Scales; Recurrence; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Time Factors | 2001 |
Serotonergic function in major depression and effect of sertraline and paroxetine treatment.
Topics: Administration, Oral; Adult; Depressive Disorder; Female; Humans; Lysergic Acid Diethylamide; Male; Middle Aged; Paroxetine; Recurrence; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Sertraline; Treatment Outcome | 2001 |
A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Long-Term Care; Male; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Recurrence; Treatment Outcome; Triazoles | 2001 |
Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus.
Topics: Aged; Female; Fluoxetine; Humans; Male; Paroxetine; Polycythemia Vera; Pruritus; Recurrence; Selective Serotonin Reuptake Inhibitors | 2002 |
Novel selective serotonin reuptake inhibitors, Part II.
Topics: Adult; Aged; Ambulatory Care; Depressive Disorder; Humans; Imipramine; Neurotransmitter Uptake Inhibitors; Paroxetine; Piperidines; Placebos; Recurrence; Serotonin; Serotonin Antagonists | 1992 |
26 other study(ies) available for paroxetine and Recrudescence
| Article | Year |
|---|---|
Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up.
Topics: Adult; Citalopram; Cognitive Behavioral Therapy; Cohort Studies; Combined Modality Therapy; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Paroxetine; Prospective Studies; Recurrence; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2015 |
Topiramate augmentation in a patient with obsessive-compulsive disorder.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Citalopram; Drug Synergism; Fear; Female; Fructose; Humans; Lorazepam; Obsessive-Compulsive Disorder; Paroxetine; Recurrence; Selective Serotonin Reuptake Inhibitors; Sertraline; Topiramate; Treatment Refusal | 2015 |
Paroxetine treatment, following behavioral suppression of PTSD-like symptoms in mice, prevents relapse by activating the infralimbic cortex.
Topics: Analysis of Variance; Anesthetics, Local; Animals; Antidepressive Agents, Second-Generation; Avoidance Learning; Cerebral Cortex; Conditioning, Classical; Cues; Disease Models, Animal; Electroshock; Freezing Reaction, Cataleptic; Male; Maze Learning; Mice; Oncogene Proteins v-fos; Paroxetine; Recurrence; Stress Disorders, Post-Traumatic; Tetrodotoxin; Time Factors | 2016 |
Relapse of tic symptoms in a patient diagnosed with obsessive-compulsive disorder and treated with high-dose paroxetine.
Topics: Adolescent; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Recurrence; Tics | 2008 |
Challenges in the identification and management of HSDD.
Topics: Combined Modality Therapy; Depressive Disorder; Female; Follow-Up Studies; Humans; Middle Aged; Paroxetine; Recurrence; Risk Factors; Sexual Dysfunctions, Psychological; Treatment Outcome | 2009 |
Agomelatine: new drug. Adverse effects and no proven efficacy.
Topics: Acetamides; Animals; Antidepressive Agents; Bias; Carcinogens; Clinical Trials as Topic; Cyclohexanols; Depression; Depressive Disorder; Double-Blind Method; Drug Approval; Europe; Fluoxetine; Humans; Hypnotics and Sedatives; Melatonin; Paroxetine; Psychiatric Status Rating Scales; Receptors, Melatonin; Recurrence; Selective Serotonin Reuptake Inhibitors; Suicide; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Bupropion; Combined Modality Therapy; Comorbidity; Database Management Systems; Humans; Inositol; Lamotrigine; Multicenter Studies as Topic; Paroxetine; Psychotherapy, Brief; Randomized Controlled Trials as Topic; Recurrence; Research Design; Risperidone; Smoking; Substance-Related Disorders; Suicide; Treatment Outcome; Triazines; United States; Vitamin B Complex | 2010 |
Delusion of Cotard's syndrome successfully treated with a dopamine agonist.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Benzothiazoles; Delusions; Depressive Disorder, Major; Dopamine Agonists; Female; Follow-Up Studies; Humans; Middle Aged; Paroxetine; Pramipexole; Recurrence; Syndrome; Treatment Outcome | 2010 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagonists; Anxiety Disorders; Citalopram; Clinical Trials, Phase II as Topic; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Multicenter Studies as Topic; Paroxetine; Pyrrolidines; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Young Adult | 2012 |
Recurrent paroxetine-induced hyponatremia.
Topics: Aged; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Paroxetine; Recurrence; Sodium Chloride | 2004 |
What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?
Topics: Adult; Adverse Drug Reaction Reporting Systems; Data Interpretation, Statistical; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paroxetine; Patient Dropouts; Recurrence; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sex Factors; Time Factors; Treatment Outcome | 2005 |
Late-onset major depression: clinical and treatment-response variability.
Topics: Activities of Daily Living; Age of Onset; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Cognition Disorders; Depressive Disorder, Major; Female; Humans; Male; Neuropsychological Tests; Paroxetine; Prognosis; Psychiatric Status Rating Scales; Recurrence; Time Factors; Treatment Outcome | 2005 |
[The serotonin syndrome].
Topics: Aged; Antipsychotic Agents; Citalopram; Depressive Disorder; Dibenzothiepins; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Middle Aged; Neurologic Examination; Paroxetine; Recurrence; Selective Serotonin Reuptake Inhibitors; Serotonin Agents; Serotonin Syndrome | 2005 |
Cost-effectiveness of antidepressants.
Topics: Ambulatory Care; Cost-Benefit Analysis; Depressive Disorder; Humans; Imipramine; Paroxetine; Patient Dropouts; Recurrence | 1994 |
LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents.
Topics: 1-Naphthylamine; Adolescent; Antidepressive Agents; Depressive Disorder; Drug Interactions; Female; Humans; Lysergic Acid Diethylamide; Male; Paroxetine; Recurrence; Sertraline; Substance-Related Disorders; Syndrome | 1994 |
Recurrent hyponatremia associated with fluoxetine and paroxetine.
Topics: Aged; Depressive Disorder; Female; Fluoxetine; Humans; Hyponatremia; Inappropriate ADH Syndrome; Paroxetine; Recurrence | 1996 |
Paroxetine in the treatment of premature ejaculation.
Topics: Adult; Antidepressive Agents, Second-Generation; Ejaculation; Humans; Male; Paroxetine; Recurrence; Sexual Dysfunctions, Psychological | 1996 |
Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Paroxetine; Piperazines; Recurrence; Serotonin Agents; Substance-Related Disorders; Triazoles; Venlafaxine Hydrochloride | 1996 |
Restless legs syndrome and paroxetine.
Topics: Adjustment Disorders; Adult; Antidepressive Agents, Second-Generation; Humans; Male; Neurologic Examination; Paroxetine; Recurrence; Restless Legs Syndrome | 1996 |
Rapid cycling triggered by pindolol augmentation of paroxetine, but not with desipramine.
Topics: Adult; Antidepressive Agents, Second-Generation; Arousal; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Paroxetine; Pindolol; Recurrence; Sympatholytics | 1996 |
Platelet serotonin and [3H]paroxetine binding correlate with recurrence of suicidal behavior.
Topics: Adolescent; Adult; Aged; Blood Platelets; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Recurrence; Serotonin; Suicide, Attempted; Tritium | 1997 |
Cost analysis of paroxetine versus imipramine in major depression.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Computer Simulation; Costs and Cost Analysis; Depressive Disorder; Humans; Imipramine; Insurance, Health, Reimbursement; Models, Economic; Paroxetine; Patient Dropouts; Recurrence; Treatment Failure; United States | 1995 |
Antidepressants for fainting spells.
Topics: Humans; Paroxetine; Recurrence; Selective Serotonin Reuptake Inhibitors; Syncope; Syncope, Vasovagal; Tilt-Table Test | 1999 |
Exacerbation of psychosis by phenylpropanolamine.
Topics: Adult; Female; Hallucinations; Humans; Methamphetamine; Nasal Decongestants; Paranoid Disorders; Paroxetine; Perphenazine; Phenylpropanolamine; Psychoses, Substance-Induced; Recurrence; Substance-Related Disorders | 2000 |
Type II error and antidepressants.
Topics: Age Factors; Aged; Antidepressive Agents; Bupropion; Delayed-Action Preparations; Depressive Disorder; Drug Therapy, Combination; False Negative Reactions; Humans; Paroxetine; Patient Selection; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Recurrence; Research Design; Treatment Outcome | 2001 |
[Paroxetine augmentation with risperidone in therapy-resistant depression].
Topics: Aged; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Paroxetine; Recurrence; Risperidone; Treatment Outcome | 2001 |